EUVIMEDEUVIMED entdecken
Crossref

Identification and validation of natural product-based KRASG12D inhibitors through structure-based virtual screening, molecular dynamics simulation, and in vitro studies

Divya Pandey, Shubham Dwivedi, Kuldeep K Roy

Molecular Diversity · 2026

DOI: 10.1007/s11030-026-11554-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2026. Verfasst von Divya Pandey und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES, Dehradun, UK, 248007, India. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Molecular Dynamics Simulation, Biological Products, Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben. Gefördert von: University of Petroleum and Energy Studies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRASG12D is a common cancer-driving mutation that fuels the progression of several aggressive cancers, particularly pancreatic, colorectal, and lung cancers. Despite its well-established role in tumor development, effective therapeutic options that directly target KRASG12D remain limited. In this study, a structure-based virtual screening strategy was employed to identify potential KRASG12D inhibitors. Molecular docking was used to screen a library of traditional Chinese medicine (TCM) compounds, followed by ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling. The top five drug-like candidates were subjected to 200 ns molecular dynamics simulations and MM-GBSA binding free-energy calculations. Three selected compounds were further evaluated in vitro, among which Rubimaillin showed notable anticancer activity with IC50 values of 1.10 ± 0.12 µM and 2.07 ± 0.02 µM against MIA PaCa-2 and PANC-1 cell lines, respectively, while displaying low toxicity toward non-tumorous HEK-293 cells (CC50 = 38.92 ± 8.49 µM). Rubimaillin also significantly inhibited cell migration and modulated key oncogenic biomarkers, including reduced KRAS protein levels, downregulation of BCL2, SOX9, and LC3 gene expression, and upregulation of p53 expression. Overall, these findings suggest that Rubimaillin may represent a suitable candidate for further investigation as a KRASG12D-targeted anticancer agent and demonstrate the value of integrating computational screening with natural product-based drug discovery approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Molecular Dynamics SimulationBiological ProductsAntineoplastic AgentsHumansMolecular Docking SimulationCell Line, TumorHEK293 CellsCell MovementDrug Screening Assays, AntitumorMutationStructure-Activity Relationship

Stichwörter der Autor:innen

CancerIn vitro studyKRASMolecular dockingMolecular dynamics simulation

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanBiological ProductsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES, Dehradun, UK, 248007, India.
  • School of Pharmacy, Graphic Era Hill University, 248002, Dehradun, India.
  • Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES, Dehradun, UK, 248007, India. kuldeepkroy@gmail.com.

Förderung

  • University of Petroleum and Energy Studies

Zitieren

APA

Pandey, D., Dwivedi, S., & Roy, K. K. (2026). Identification and validation of natural product-based KRASG12D inhibitors through structure-based virtual screening, molecular dynamics simulation, and in vitro studies. Molecular Diversity. https://doi.org/10.1007/s11030-026-11554-x

Vancouver

Pandey D, Dwivedi S, Roy KK. Identification and validation of natural product-based KRASG12D inhibitors through structure-based virtual screening, molecular dynamics simulation, and in vitro studies. Molecular Diversity. 2026. doi:10.1007/s11030-026-11554-x

BibTeX
@article{Pandey2026,
  author = {Pandey, Divya and Dwivedi, Shubham and Roy, Kuldeep K},
  title = {Identification and validation of natural product-based KRASG12D inhibitors through structure-based virtual screening, molecular dynamics simulation, and in vitro studies},
  journal = {Molecular Diversity},
  year = {2026},
  doi = {10.1007/s11030-026-11554-x}
}
Kostenlos starten →